anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: A subset of exceptionally rare primary renal perivascular epithelioid cell tumours (PEComas) that harbour Xp11.2 translocation have been reported, but no larger series devoted to this topic have been published.
METHODS AND RESULTS: We describe the clinicopathological and molecular features of 10 renal PEComas, collected from our routine and consultation files. There were five female and five male patients aged 14-65 (median: 32 years). One patient had a history of childhood neuroblastoma, but no patients were known to have a tuberous sclerosis complex or other hereditary disorder. Complete surgical excision was the treatment for all patients. The available follow-up in five patients indicated a favourable outcome in 4/5 cases. Tumour size ranged from 2.8 to 15.2 cm (median, 5.2 cm). Immunohistochemistry revealed consistently strong TFE3 expression in all tumours, whereas PAX8 and keratin cocktails were uniformly negative. Other positive markers included HMB45 (7/9 tumours), CathepsinK (7/9 tumours), and CD117 (KIT) (3/5 tumours). TFE3 rearrangements were detected in 8/9 tumours (by targeted RNA sequencing in seven and by FISH in one). The identified fusion partners included SFPQ (n = 2) and one tumour each with ASPSCR1, ZC3H4, MED15, RBMX, and PRCC. One tumour that lacked TFE3 rearrangement by next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) revealed a large intrachromosomal deletion involving PKD1 and TSC2 by DNA-based NGS.
CONCLUSION: This study highlights the morphologic and genetic diversity of TFE3-rearranged primary renal PEComas and underlines the value of surrogate TFE3 immunohistochemistry in identifying them. The lack of PAX8 and keratin expression represents the mainstay for distinguishing these tumours from MiTF-associated renal cell carcinomas. In addition, we report rare (ZC3H4, RBMX) and novel (MED15) TFE3 fusion partners in PEComa.
BACKGROUND: Perforated peptic ulcer remains one of the most common surgical emergencies in India with significant morbidity and mortality. The aim of this study was to identify the perioperative risk factors influencing the post-operative morbidity and mortality in patients with perforated peptic ulcer disease.
METHODS: Five-hundred patients who underwent surgery for perforated peptic ulcer in our institution in the preceding 8 years were included in this observational retrospective study. Their clinical presentations, peri-operative managements were studied and analysed.
RESULTS: Five hundred cases were analysed of which 96% were males. Mean age was 46.5 years. A total of 160 patients had duodenal perforation and 328 had gastric perforation with a mean size of 8.6 mm. Most patients (96.2%) underwent omental patch closure of the perforation with mean length of hospitalization being 14 days. The most common major and minor postoperative complications were prolonged intubation and pulmonary complaints respectively. Re-exploration was needed in 6.2% of cases with a post-operative leak rate of 5.8%. Age >60 years, presence of comorbid illnesses, shock at presentation and perforation size >1 cm were identified as independent predictors of postoperative morbidity. Overall mortality was 11.6% while specific mortality among males and females were 11.8% and 5% respectively. Age >60 years, shock at presentation, presence of abdominal rigidity and size of perforation >1 cm were independent predictors of mortality.
CONCLUSION: Old age, comorbidities, shock at presentation, perforation size >1 cm, higher ASA grade, prolonged surgery and biliopurulent contamination >500 mL were independent predictors of both increased post-operative morbidity and mortality.
The current model of care delivery has demanded a technical-assistance approach that prioritizes the quality of care, as indissolubly concerns the employment of technology, knowledge, the centrality of dialogue between professionals and patients and individualized choice resources deemed suitable for safe delivery. Seeking to implement a less interventionist care with evidence-based practice and greater incentive to vaginal delivery, the programs were created humanization of labor and birth, with the use of various non-pharmacological resources. This study aimed to evaluate the effectiveness of the combination of non-pharmacological resources during the dilation in relieving the pain of the mothers. The research will be of type randomized controlled trial, consisting of low-risk primigravidae admitted at the Reference Center for Women's Health in Ribeirão Preto. The mothers will be distributed in two groups (intervention protocol features non-drug) and Control (routine maternity) and will be evaluated before and after application of each resource, and the control group in the same time according to cervical dilation. Evaluation will be conducted by a visual analog scale and / or facial pain and pain location diagram and postpartum will be applied a validated questionnaire Experience and Satisfaction with childbirth. After collecting the data, the groups are statistically analyzed using the linear regression model with mixed effects (fixed and random), taking into account a value of p \<0.05 to obtain the statistical significance of 5%.
The present invention discloses a medicament for treating various kinds of cancer, which belongs to the technical field of traditional Chinese medicaments. The medicament is prepared from a medicament No. 1, a medicament No. 2 and a liquid medicament, wherein the medicament No. 1 is prepared from alga, common selfheal fruit-spike, weeping forsythiae capsule, cochinchina momordica seed, curare, langdu root and honeysuckle, and the raw materials are pulverized and made into capsules; the medicament No. 2 is prepared from Hirudo, centipede and scorpion, and the raw materials are pulverized and made into capsules; the liquid medicament is prepared from hedyotic diffusa, Herba Scutellariae Barbatae and water, the raw materials are heated, and the liquid medicament is decocted to 25 ml. The medicament for treating various kinds of cancer has the advantages of notable therapeutic effect, low cost and no pain of patients, and can heal various kinds of cancer.
LSVT BIG is a commonly used protocol to manage functional movement for those with Parkinson's Disease. This study measured postural control and gait parameters following a 4-week course of LSVT BIG therapy.
The composition contains at least one alkaline agent, at least one peroxy salt and a combination of water-soluble polymer and nonionic amphiphilic polymer with at least one fatty chain. The composition comprises, in medium appropriate for bleaching, at least one alkaline agent (A), at least one peroxy salt (B), and a combination of at least one water-soluble natural or synthetic thickening polymer (C) and nonionic amphiphilic polymer (D) with at least one fatty chain. The composition may also contain an anionic amphiphilic polymer (E) containing at least one fatty chain and additional auxiliary agents such as oxygen release control agents, surfactants, mineral and vegetable oils, waxes, granulation promoters, binders, mineral fillers, opacity agents, colorants, sequestrants and fragrances. The composition can be in the form of a powder or suspension or dispersion of powder in anhydrous organic liquid, and preferably contains 20-70 (preferably 30-60) wt.% of (B), 0.03-30 (preferably 0.3-15) wt.% of (C), 0.03-30 (preferably 0.3-15) wt.% of (D) (at D/E wt. ratio 10/1 to 1/10, preferably 5/1 to 1/5) and 0.03-30 wt.% of (E). Independent claims are also included for: (1) the use of the composition as claimed in the preparation of a bleaching composition by addition, directly before use, of an aqueous solution of hydrogen peroxide; (2) a process of bleaching of keratin fibers, especially hair, which comprises mixing, directly before use, an anhydrous bleaching composition as above and an aqueous solution of hydrogen peroxide, applying the obtained mixture onto the hair area to be bleached, leaving for a period necessary to produce desired bleaching effect, removing bleaching mixture by rinsing with water and shampooing and drying; and (3) a kit for bleaching keratin fibers, especially hair, which contains at least two compartments of which one contains anhydrous composition as claimed while the other contains aqueous solution of hydrogen peroxide.
The invention discloses application of ginkgo leaf total lactones in preparation of a medicament for preventing or treating deafness and tinnitus. The ginkgo leaf total lactones are extracted from ginkgo leaves, the lactone component content is 50 to 99 percent by HPLC (High Performance Liquid Chromatography) detection, and the ginkgo leaf total lactones mainly comprise four chemical components, namely ginkgo lactone A, ginkgo lactone B, ginkgo lactone C and ginkgo seed lactone. The inventor performs experiments of the ginkgo leaf total lactones on a rat audition effect, and the results show that the ginkgo leaf total lactones have certain protection effect on the rat audition, the effect of the ginkgo leaf total lactones is obviously superior to that of ginkgo leaf extract and a quantitative effect relationship is formed. Therefore, the ginkgo leaf total lactones can be used for preparing the medicament for preventing or treating the deafness and the tinnitus. The medicament is a medicinal composition prepared from the ginkgo leaf total lactones and medicinal auxiliary materials according to a conventional method. The medicament can be prepared into oral preparations such as tablets, capsules and the like, can also be prepared into injection preparations such as injection, freeze-dried powder and the like, and can further be prepared into patches and the like.
Wound care devices having a topically applied silver-based antimicrobial finish are provided. The finish comprises at least one silver ion-containing compound and at least one binder compound. The finish may be applied to a target substrate, such as a fiber, fabric, film, foam, hydrogel, or hydrocolloid to provide a single layer antimicrobial wound care device. Alternatively, a silver-containing layer may be combined with one or more additional layers of target substrate to provide a composite antimicrobial wound care device. The device may also contain an odor-absorbing component capable of reducing or eliminating odors that are inherently associated with infectious wounds. The invention also provides a method for making the wound care device and a composition of matter comprising the silver-based antimicrobial finish.
Volumex (Iodinated I 131 Albumin Injection) is a diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous use. Each mL of sterile, nonpyrogenic, aqueous, colorless to very pale yellow solution provides approximately 10 mg protein (albumin human), 16 mg dibasic sodium phosphate, 1.6 mg monobasic sodium phosphate, not more, than 0.4 mg guanidine hydrochloride, sodium chloride for isotonicity, and 9 mg benzyl alcohol as a preservative. The stabilizer acetyltryptophanate and sodium caprylate have a concentration of less than 0.0089M. The pH has been adjusted to 7.2-7.8 with sodium hydroxide or hydrochloric acid.

Volumex was prepared from blood that was nonreactive when tested for hepatitis B surface antigen (HBsAg). The structure of the complex is unknown.
A systematic review suggested no overall difference in the rates of IBS in East and West . In a population based study from Pakistan. Prevalence of IBS was assessed using Rome II criteria in relation to psychological distress, disability and life events in men and women separately. The prevalence of Rome II IBS was 13.3% which was higher than most population-based studies in Asia using Rome II criteria and similar to reports from Turkey and Malaysia.The findings also suggest equal sex ratio of IBS in urban Pakistan which may be because of the close association between marked distress and IBS in men similar to that found in women in the west.The results indicated that diarrhea-predominant IBS was associated with less disability compared to the constipation-predominant IBS which was associated with marked disability. This might be explained by the explanatory models; constipation is considered harmful as toxins or other harmful substances are retained within the body whereas diarrhea is not considered harmful as any toxins etc are removed from the body. Distress and life events contributed independently to high disability. In psychological treatments there is an assumption that there are some critical features which need to be addressed in the treatment process such as stress and anxiety; it also suggests that stress has a major role in increasing IBS symptoms as well as stress reactivity which results in IBS symptoms. The goal of cognitive-behavioral treatments is to increase awareness regarding the association between stress, thoughts, and IBS symptoms, it is important to identify and modify cognitive appraisals and to change depressive and/or anxiety-based schema. These interventions play a major role in decreasing IBS symptoms severity and associated anxiety and depression when compared to no treatment or standard medical care.
PURPOSE: A composition for enhancing radiosensitivity, which containing microRNA-21 inhibitor is provided to enhance radiosensitivity of cancer cells and the effect of radiation therapy. CONSTITUTION: A composition for enhancing radiosensitivity contains microRNA-21 inhibitor. The microRNA-inhibitor is antisense nucleic acid molecule which complementarily binds to the microRNA-21 sequence. The microRNA-inhibitor is siRNA(small interfering RNA), RNA aptamer, or ribozyme which is specific to the microRNA. The antisense nucleic acid molecule is anti oligonucleotide. The length of the anti oligonucleotide is 15-40 nucleotide. The anti oligonucleotide comprises sequence of the sequence number 1. The anti oligonucleotide is contained in an expression vector for intracellular delivery. The expression vector is lentivirus, retrovirus, adenovirus, herpes virus, or avipox virus.
The 1-substituted 8-iodo-6-phenyl-4H-s-triazolo[3,4c]thieno[2,3e]1,4-diazepines of the formula I, as well as their physiologically tolerated acid addition salts, are prepared by cleaving a 4,1-oxazepine of the formula VII at the oxygen atom by treatment with a strong mineral acid, adding a phosphorus or sulphur halide to the hydro halide which forms, reacting the dihalide thus obtained with ammonia or substances giving rise to ammonia, and dehydrogenating the product. The substituents in the formulae I and VII have the meanings given in Patent Claim 1. Further preparation processes are given in Patent Claims 7 to 11 and 13. The compounds exhibit valuable therapeutic properties, in particular tranquillising, tension-releasing and sedative activity, as well as an intensive anticonvulsive effect, in association with extraordinarily low toxicity. In addition, they can be employed for improving feed uptake in mammals. <IMAGE>
Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-? ligand or a TGF-? receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and/or through engagement of a TGF-? ligand or a TGF-? receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.
Ensuring the safety of analgesics during lactation is crucial for women of childbearing potential. Available data regarding the transfer of nalbuphine for postoperative acute pain via breast milk are limited to the postmarketing experience. This lactation study aimed to assess nalbuphine and dinalbuphine sebacate concentrations in breast milk from lactating women with postoperative pain treated with dinalbuphine sebacate extended-release injection (150 mg dinalbuphine sebacate/2 mL Naldebain). Breast milk was collected throughout the 5-day posthospitalization interval from 20 mothers injected with one dose of extended-release dinalbuphine sebacate intramuscularly. Maternal safety was assessed during the study period. Nalbuphine was detectable in 71% of milk samples collected from all mothers, whereas dinalbuphine sebacate was undetectable or below the quantitation limit (0.1 ng/mL). The mean nalbuphine concentration in milk was approximately 10.55 ng/mL, with the peak concentration reaching up to 12.7 ng/mL. The mean relative infant dose was 0.39% (coefficient of variation, 65%). The mean pain intensity at rest was reduced to mild pain from Day 2 morning to discharge. Overall, the maternal safety profile was tolerable. The breast milk of women who receive one dose of dinalbuphine sebacate injection postpartum contains low nalbuphine concentration. In addition, dinalbuphine sebacate injection potentially reduces maternal pain intensity during the first postpartum week and offers low toxicity risk among breastfed infants.
In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
<P>PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsified cosmetic having excellent dispersibility of metal oxide powder, improved emulsifiability and stability with time and improved makeup lasting quality.  <P>SOLUTION: This oil-in-water type emulsified cosmetic comprises a component (a) of an organosilicone resin, a component (b) of an hydrophilic nonionic surfactant, a component (c) of a lipophilic nonionic silicone-based surfactant and a component (d) of metal oxide powder. In the oil-in-water type emulsified cosmetic, the component (a) is an acrylic-silicone graft copolymer. In the oil-in- water type emulsified cosmetic, the component (c) is a polyether modified organopolysiloxane. Any of the oil-in-water type emulsified cosmetics contains higher fatty acid soap as a component (e).  <P>COPYRIGHT: (C)2003,JPO
An integrated scaffold for bone tissue engineering has a tubular outer shell and a spiral scaffold made of a porous sheet. The spiral scaffold is formed such that the porous sheet defines a series of spiral coils with gaps of controlled width between the coils to provide an open geometry for enhanced cell growth. The spiral scaffold resides within the bore of the shell and is integrated with the shell to fix the geometry of the spiral scaffold. Nanofibers may be deposited on the porous sheet to enhance cell penetration into the spiral scaffold. The spiral scaffold may have alternating layers of polymer and ceramic on the porous sheet that have been built up using a layer-by-layer method. The spiral scaffold may be seeded with cells by growing a cell sheet and placing the cell sheet on the porous sheet before it is rolled.
Hysterectomy is the most common gynecological procedure worldwide. . There has been a increasing interest towards to more minimally invasive procedures in the past decade. Hysterectomy operation anxiety is a complex phenomenon affected by various parameters. Patients' anxiety may be affected by their age, gender, educational status,type of operation and personality. Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
The invention discloses a capsule pill capable of enhancing memory, which belongs to the technical field of Chinese herba preparation. The capsule pill capable of enhancing memory is prepared from granulesten, rhizoma acori graminei, fushen, astragalus mongholicus, codonopsis pilosula, dried longan pulp and English walnut seed. The medicines contain nutrient substances which are most required by the brain. The capsule pill can relieve stuffy nose and nerves, soothe the nerves and restore consciousness. Patients are in high spirits because of full Qi-blood. The memory ability is enhanced, and the quality of working, studying and living is improved.
Single center, investigator driven, double blinded, randomized with Caduet 5/10mg vs placebo. The participants visited with investigators on a monthly bases to evaluate the BP, weight, and obtain the waist measurements, and counseling. OGTT was performed at the beginning and the end of the study. Lipid and glucose parameters were measured 5 times in duration of the study period.

Exercise physiologists and dietitians completed the baseline evaluations and provided recommendations throughout the study period in person, via phone or e-mail: per subject preference. VO2 max was measured at the beginning and end of the study. Pedometers dispensed to encourage physical activity.
Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
A treatment product is disclosed including a natural cellular DNA repair ingredient in combination with at least one other functional component. The natural cellular DNA repair ingredient may be derived from  Uncaria tomentosa, Acacia plumose , and/or  Uncana rhynchophylla . The treatment product may be internally administered, for example, where the at least one other functional component is selected from pyruvate, niacin, ubiquinone, lipoic acid, L-aspartic acid, citric acid, riboflavin, thiamine, potassium bicarbonate, sodium bicarbonate, and magnesium citrate. The treatment product may be topically administered, for example, where the at least one other functional component includes an amino acid, zinc and a hydroxylating active. The amino acid may be glycine, lysine, and/or proline. The hydroxylating active may be alpha-ketoglutarate and/or vitamin C. The at least one other functional component increases ATP production at a cellular level and/or enhances effectiveness of the natural cellular DNA repair ingredient at a cellular level.